Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

被引：50

作者：

Bannerji, Rajat ^{[1
]}

Allan, John N. ^{[2
]}

Arnason, Jon E. ^{[3
]}

Brown, Jennifer R. ^{[4
]}

Advani, Ranjana H. ^{[5
]}

Barnes, Jeffrey A. ^{[6
]}

Ansell, Stephen M. ^{[7
]}

O'Brien, Susan M. ^{[8
]}

Chavez, Julio ^{[9
]}

Duell, Johannes ^{[10
]}

David, Kevin A. ^{[1
]}

Martin, Peter ^{[11
]}

Joyce, Robin M. ^{[3
]}

Charnas, Robert ^{[12
]}

Ambati, Srikanth R. ^{[12
]}

Adriaens, Lieve ^{[12
]}

Ufkin, Melanie ^{[12
]}

Zhu, Min ^{[12
]}

Li, Jingjin ^{[12
]}

Gasparini, Peter ^{[12
]}

Ibrahim, Anfal ^{[12
]}

Jankovic, Vladimir ^{[12
]}

Fiaschi, Nathalie ^{[12
]}

Aina, Olulanu ^{[12
]}

Zhang, Wen ^{[12
]}

Deering, Raquel P. ^{[12
]}

Hamon, Sara ^{[12
]}

Thurston, Gavin ^{[12
]}

Murphy, Andrew J. ^{[12
]}

Weinreich, David M. ^{[12
]}

Yancopoulos, George D. ^{[12
]}

Lowy, Israel ^{[12
]}

Sternberg, David ^{[12
]}

Topp, Max S. ^{[13
]}

机构：

[1] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA

[2] Weill Cornell Med, Long Isl City, NY USA

[3] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA

[4] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[5] Stanford Univ, Stanford, CA 94305 USA

[6] Massachusetts Gen Hosp, Boston, MA 02114 USA

[7] Mayo Clin, Rochester, MN USA

[8] Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Irvine, CA USA

[9] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[10] Univ Klinikum Wurzburg, Wurzburg, Germany

[11] Weill Cornell Med, New York, NY USA

[12] Regeneron Pharmaceut Inc, Tarrytown, NY USA

[13] Univ Wurzburg, Wurzburg, Germany

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-122451

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

762

引用

页数：8

共 50 条

[1] A Phase 2 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody (Ab), in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)
Topp, Max S.
Duell, Johannes
Li, Jingjin
Jankovic, Vladimir
Lowy, Israel
Sternberg, David
Adriaens, Lieve
Peterman, Mary
Ambati, Srikanth R.
Bannerji, Rajat
BLOOD, 2019, 134
[2] Emerging Clinical Activity of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL), and Other B-Cell Non-Hodgkin Lymphoma (B-NHL) Subtypes
Bannerji, Rajat
Arnason, Jon E.
Advani, Ranjana
Brown, Jennifer R.
Allan, John N.
Ansell, Stephen M.
Barnes, Jeffrey
O'Brien, Susan M.
Chavez, Julio C.
Duell, Johannes
Lowy, Israel
Charnas, Robert
Sternberg, David
Ambati, Srikanth
Adriaens, Lieve
Ufkin, Melanie
Yan, Xiaoyu
Li, Jingjin
Navarro, Mark
Gasparini, Peter
Jankovic, Vladimir
Fiaschi, Nathalie
Zhang, Wen
Hamon, Sara
Thurston, Gavin
Topp, Max S.
BLOOD, 2018, 132
[3] Safety and Preliminary Clinical Activity of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with B-NHL Previously Treated with CD20-Directed Antibody Therapy
Bannerji, Rajat
Advani, Ranjana H.
Brown, Jennifer R.
Arnason, Jon E.
Barnes, Jeffrey A.
Allan, John N.
Ansell, Stephen M.
O'Brien, Susan M.
Chavez, Julio C.
Adriaens, Lieve
Ufkin, Melanie
Kostic, Ana
Paccaly, Anne Josee
Gao, Bo
Lowy, Israel
Sternberg, David
Topp, Max S.
BLOOD, 2017, 130
[4] PHARMACOKINETICS AND EXPOSURE-RESPONSE FOR REGN1979, A BISPECIFIC ANTI-CD20 X ANTI-CD3 ANTIBODY, IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA.
Yang, F.
Zhu, M.
Toroghi, M.
Putluri, D.
Yan, H.
Davis, J.
DiCioccio, A.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S120 - S120
[5] A Phase 2 Study of Odronextamab (REGN1979), a CD20 x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Kim, Tae Min
Alonso, Arancha
Prince, Miles
Taszner, Michal
Cho, Seok-Goo
Stevens, Don A.
Poon, Michelle
Lim, Francesca
Le Gouill, Steven
Carpio, Cecilia
Keating, Mary-Margaret
Adriaens, Lieve
Ufkin, Melanie
Sabir, Ayesha
Li, Jingjin
Jankovic, Vladimir
Zhu, Min
Brouwer-Visser, Jurriaan
Leng, Siyang
Sirulnik, L. Andres
Chaudhry, Aafia
Ambati, Srikanth R.
Seog, Kim Won
BLOOD, 2020, 136
[6] Safety and efficacy of a novel anti-CD20/CD19 bispecific CAR T-cell therapy (C-CAR039) in relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL).
Liang, Aibin
Zhou, Lili
Li, Ping
Yu, Wenjuan
Yang, Min
Xu, Yangyang
Ye, Shiguang
Zhu, Judy
Huang, Jiaqi
Zhang, Yan
Li, Lanfang
Zhao, Jing
Li, Jing
Zheng, Chengxiao
Zhu, Kevin
Lan, Liping
Zhang, Huilai
Zhou, Daobin
Yao, Yihong
Jin, Jie
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[7] TRANSLATIONAL FINDINGS FOR REGN1979, A HUMAN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY: FROM PRECLINICAL TO FIRST-IN-HUMAN STUDY IN PATIENTS WITH CD20+B-CELL MALIGNANCIES.
Zhu, M.
Smith, E.
Kirshner, J.
Toroghi, M.
Davis, J.
Di-Cioccio, A.
Retter, M.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S103 - S103
[8] Phase 1 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+B-Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy
Bannerji, Rajat
Brown, Jennifer R.
Advani, Ranjana H.
Arnason, Jon
O'Brien, Susan M.
Allan, John N.
Chavez, Julio C.
Barnes, Jeffrey A.
Joyce, Robin
Ansell, Stephen
Topp, Max S.
Adriaens, Lieve
Ufkin, Melanie
Kostic, Ana
Paccaly, Anne
Gao, Bo
Trail, Pamela A.
Lowy, Israel
Brownstein, Carrie
BLOOD, 2016, 128 (22)
[9] Polatuzumab vedotin, venetoclax, and an anti-CD20 monoclonal antibody in relapsed/refractory B-cell non-Hodgkin lymphoma
Yuen, Sam
Phillips, Tycel J.
Bannerji, Rajat
Marlton, Paula
Gritti, Giuseppe
Seymour, John F.
Johnston, Anna
Arthur, Christopher
Dodero, Anna
Sharma, Sunil
Hirata, Jamie
Musick, Lisa
Flowers, Christopher R.
AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (07) : 1281 - 1289
[10] Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20 X anti-CD3 bispecific diabody
Xiong, DS
Xu, YF
Liu, HZ
Peng, H
Shao, XF
Lai, ZZ
Fan, DM
Yang, M
Han, JL
Xie, Y
Yang, CZ
Zhu, ZQ
CANCER LETTERS, 2002, 177 (01) : 29 - 39

← 1 2 3 4 5 →